Amgen Inc. $AMGN Holdings Trimmed by Elevated Capital Advisors LLC

Elevated Capital Advisors LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 64.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 654 shares of the medical research company’s stock after selling 1,211 shares during the quarter. Elevated Capital Advisors LLC’s holdings in Amgen were worth $276,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. State Street Corp boosted its stake in shares of Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after buying an additional 11,656,755 shares during the period. MW Advisory LLC purchased a new position in shares of Amgen during the 2nd quarter valued at $1,054,000. Baird Financial Group Inc. increased its stake in shares of Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after acquiring an additional 5,496 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in shares of Amgen by 105.8% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock worth $5,696,000 after acquiring an additional 6,947 shares during the last quarter. Finally, Nilsine Partners LLC purchased a new stake in shares of Amgen during the second quarter worth $3,329,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Amgen Stock Performance

Shares of AMGN opened at $465.23 on Wednesday. The company’s fifty day moving average is $423.79 and its 200-day moving average is $379.39. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The firm has a market cap of $251.65 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. During the same quarter last year, the firm earned $5.64 EPS. Amgen’s revenue for the quarter was up 8.5% on a year-over-year basis. Equities analysts expect that Amgen Inc. will post 23.33 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is presently 58.47%.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on AMGN. TD Cowen lifted their price objective on Amgen from $452.00 to $531.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Guggenheim upped their target price on Amgen from $378.00 to $435.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. HSBC lowered Amgen from a “buy” rating to a “hold” rating and dropped their target price for the stock from $445.00 to $425.00 in a research report on Thursday, September 10th. Canaccord Genuity Group raised their price target on Amgen from $384.00 to $440.00 and gave the stock a “hold” rating in a research note on Wednesday, November 4th. Finally, Argus lifted their price target on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $422.76.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.